

Curriculum Vitae

Name: Thomas Jack Schnitzer, M.D., Ph.D.

Office Addresses

Administration: Feinberg School of Medicine
710 N. Lake Shore Drive
Abbott Hall, Room 1020
Chicago, IL 60611

Clinical Affairs: Rehabilitation Institute of Chicago
345 E. Superior Street
Chicago, IL 60611

EDUCATION:

McDonogh School, Maryland	1960-1964
Princeton University, B.A., Biochemistry, Summa Cum Laude	1964-1967
Harvard Medical School, M.D., Cum Laude	1967-1971
Imperial Cancer Research Fund Laboratories, Council for National Academic Awards, London, England, Ph.D.	1976-1979

GRADUATE TRAINING:

Internship, Johns Hopkins Hospital, Baltimore, Maryland	1971-1972
Residency, Johns Hopkins Hospital, Baltimore, Maryland	1972-1973
Research Associate, National Institutes of Health, National Institute of Allergy and Infectious Disease, Laboratory of Infectious Disease, Bethesda, Maryland	1973-1975
Fellow, Medical Research Council Rheumatism Unit, Taplow, England	1975-1976

TEACHING APPOINTMENTS:

Medical Scientists, Imperial Cancer Research Fund Laboratories, London, England	1976-1979
Clinical Consultant, Pediatric Infectious Diseases, Great Ormond Street Hospital for Sick Children, London England	1977-1979
Associate Professor, Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan	1979-1985
Associate Professor, Department of Internal Medicine, University Michigan Medical School, Ann Arbor, Michigan	1979-1985

TEACHING APPOINTMENTS: (continued)

Professor and Director, Section of Geriatric Medicine, Department of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois	1985-1995
Director, Department of Medicine and Rehabilitation, Marianjoy Rehabilitation Center, Wheaton, Illinois	1986-1988
Medical Director, Plymouth Place Retirement Community, LaGrande Park, Illinois	1989-1993
Co-Director, Center for Research on Health and Aging, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois	1989-1990
Medical Director, Johnston R. Bowman Health Center for the Elderly, Chicago, Illinois	1990-1996
Director, Office of Clinical Research and Training Northwestern University, Chicago, Illinois	1997-2007
Assistant Dean for Clinical Research, Northwestern University Feinberg School of Medicine, Chicago, Illinois	1997-2007
Professor, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois	1997-Present
Professor, Department of Physical Medicine and Rehabilitation, Northwestern Feinberg School of Medicine, Chicago Illinois	2007-Present

CONSULTING POSITIONS:

Clinical Consultant, Pediatric Infectious Diseases, Great Ormond Street Hospital for Sick Children, London, England	1977-1979
Veterans Administration Hospital, Department of Internal Medicine, Ann Arbor, Michigan	1979-1985
Marianjoy Rehabilitation Center, Wheaton, Illinois	1986-1997

CERTIFICATION AND LICENSURE:

American Board of Internal Medicine	1974
Subspecialty Board of Rheumatology	1978
Board Eligible, Infectious Disease	
Illinois License 036-071815	

MILITARY SERVICE:

United States Public Health Service	1973-1975
-------------------------------------	-----------

HONORS AND AWARDS:

University Scholar, Princeton University	1964-1967
Phi Beta Kappa Prize, Princeton University	1967
Biology Senior Book Prize, Princeton University	1967
B.A., Summa Cum Laude, Princeton	1967
M.D., Cum Laude, Harvard University	1971
Exchange Scientist, Royal Society and Czechoslovak Academy of Sciences, Bratislava	1977, 1978
EMBO Fellowship, Visiting Scientist, Institut Pasteur, Paris	1978-1979

HONORS AND AWARDS: (continued)

Arthritis Foundation Senior Investigator	1980-1985
Willard L. Wood., M.D., Endowed Chair, Professor of Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center	1986-1997

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES:

- American Association for Advancement of Science
- American College of Rheumatology
- American Federation for Clinical Research
- American Geriatrics Society
- American Society for Clinical Investigation
- American Society of Microbiology
- Central Society for Clinical Research
- Osteoarthritis Research Society
- Phi Beta Kappa
- Sigma Xi

TEACHING ACTIVITIES:

Lectures offered in Microbiology, Internal Medicine, and Public Health	1979-1985
Coordinator, Medical School Pre-Clinical Rheumatology	1984-1985
Lectures offered in Geriatrics, Internal Medicine and Rheumatology	1986-Present

COMMITTEE AND ADMINISTRATIVE SERVICE:

Medical and Scientific Committee, Arthritis Foundation, Michigan Chapter	1981-1984
Secretary-Treasurer, Michigan Rheumatism Society	1983-1984
Representative, American Hospital Association-Section for Long Term Care Services	1990-1993
Chairman, Medical and Scientific Committee, Arthritis Foundation, Michigan Chapter	1984-1985
Membership Committee, American Rheumatism Association	1984-1989
Committee on Committees, Rush-Presbyterian-St. Luke's Medical Center	1989-1992 1995-1997
Committee on Dialogue, Rush-Presbyterian-St. Luke's Medical Center	1989-1992 1993-1997
Midwest Home Support Services Research Sub-Committee	1989-1990
Board of Directors, Arthritis Foundation, Illinois Chapter	1990-1997

COMMITTEE AND ADMINISTRATIVE SERVICE: (continued)

Utilization Review Committee, Rush-Presbyterian-St. Luke's Medical Center	1990-1997
Senior Faculty Appointments and Promotions Committee, Rush-Presbyterian St. Luke's Medical Center	1991-1994
Nominating Committee, Arthritis Foundation, Illinois Chapter	1992-1995
Vice-President for Education, American Academy of Pharmaceutical Physicians	1997-1999
Research Council, NUMS	1997-1999
Advisory Editor, <i>Arthritis and Rheumatism</i>	1995-2000
Advisory Board, Lurie Cancer Center, NUMS	1997-1999
NU IRB Advisory Board	1998-Present
Clinical Council, NUMS	1999-2004
Scientific Advisory Board, National Osteoporosis Foundation	2002-2005
NIH Study Sections, Ad Hoc Reviewer	2001-Present
PhRMA-AAMC Forum	2001-2004
DIA CME Committee	2003-2006
Editorial Board, Arthritis Care and Research	2003-Present
Editor, Current Osteoporosis Reports	2004-Present
Editorial Board, Therapy	2004-Present
Chair, DSMB, Northwestern GCRC	2004-Present
AAMC Clinical Research Task Force	2004-2006
Editorial Board, Open Rheumatology Journal	2007-Present

BIBLIOGRAPHY

COMPLETED PUBLICATIONS:

1. Hodes DS, **Schnitzer TJ**, Kalica AR, Camargo E, Chanock RM: Inhibition of respiratory syncytial, parainfluenza 3 and measles virus by 2-deoxy-D-glucose. *Virology* 63:201-208, 1975.
2. **Schnitzer TJ**, Hodes DS, Gerin J, Camargo E, Chanock RM: Effect of 2-deoxy-D-glucose and glucosamine on the growth and functions of respiratory syncytial and parainfluenza 3 viruses. *Virology* 67:306-309, 1975.
3. **Schnitzer TJ**, Richardson LS, Chanock RM: Growth and genetic stability of the ts-1 mutant of respiratory syncytial virus at restrictive temperatures. *J Virol* 17:431-438, 1976.
4. **Schnitzer TJ**, Ansell BM: Amyloidosis in juvenile chronic polyarthritis. *Arth Rheum* 20:53-71S, 1977.
5. Richardson LS, **Schnitzer TJ**, Belshe RB, Camargo E, Prevar DA, Chanock RM: Isolation and characterization of further defective clones of a temperature-sensitive mutant (ts-1) of respiratory syncytial virus. *Arch Virol* 54:53-60, 1977.
6. Belshe RB, Richardson LS, **Schnitzer TJ**, Prevar DA, Camargo E, Chanock RM: Further characterization of the complementation group B temperature-sensitive mutant of respiratory syncytial virus. *J Virol* 24:8-12, 1977.
7. **Schnitzer TJ**, Ansell BM, Hawkins GT, Marshall WC: Significance of rubella virus infection in juvenile chronic polyarthritis. *Ann Rheum Dis* 36:468-470, 1977.
8. **Schnitzer TJ**, Zavada J, Weiss RA: Pseudotypes of vesicular stomatitis virus with the envelope properties of mammalian and primate retroviruses. *J Virol* 23:449-454, 1977.
9. **Schnitzer TJ**: Phenotypic mixing between two primate oncoviruses. *J Gen Virol* 42:199-206, 1979.
10. **Schnitzer TJ**, Dickson C, Weiss RA: Morphological and biochemical characterization of viral particles produced by the ts 045 mutant of vesicular stomatitis virus at restrictive temperature. *J Virol* 29:185-195, 1979.
11. **Schnitzer TJ**, Lodish HF: Non-infectious vesicular stomatitis virus particles deficient in the viral nucleocapsid. *J Virol* 29:443-447, 1979.
12. **Schnitzer TJ**, Gonczol E: Phenotypic mixing between murine oncoviruses and murine cytomegalovirus. *J Gen Virol* 43:691-695, 1979.

COMPLETED PUBLICATIONS: (continued)

13. **Schnitzer TJ**, Watkins JF: Persistent infection of a cell line of mouse origin after cell fusion by u.v.-inactivated Sendai virus. *J Gen Virol* 46:219-226, 1980.
14. **Schnitzer TJ**, Weiss RA, Juricek DK, Ruddle FH: Use of VSV pseudotypes to map viral receptor genes: Assignment of RD114 virus receptor gene to human chromosome 19. *J Virol* 35:575-580, 1980.
15. **Schnitzer TJ**: Characterization of a simian foamy virus isolated from a spontaneous primate lymphoma. *J Med Primat* 10:312-328, 1981.
16. **Schnitzer TJ**: Simian foamy virus pseudotypes of vesicular stomatitis virus: Production and use in sero-epidemiologic studies. *J Gen Virol* 59:203-206, 1982.
17. Ytterberg SR, **Schnitzer TJ**: Serum interferon levels in patients with systemic lupus erythematosus. *Arth Rheum* 25:401-406, 1982.
18. Moidel R, Schwartz S, **Schnitzer TJ**: Regulation of concanavalin A-activated suppressor cell activity by interferon. *J Rheum* 9:665-670, 1982.
19. Gouvea V, **Schnitzer TJ**: Polymorphism of the genomic RNAs among the avian reoviruses. *J Gen Virol* 61:87-91, 1982.
20. Gouvea V, **Schnitzer TJ**: Polymorphism of the migration of double-stranded RNA genome segments of avian reoviruses. *J Virol* 43:466-471, 1982.
21. **Schnitzer TJ**, Ramos T, Gouvea V: Avian reovirus polypeptides: Analysis of intracellular viral-specified products, virions, top component and cores. *J Virol* 43:1006-1014, 1982.
22. Gouvea V, **Schnitzer TJ**: Pathogenicity of avian reoviruses: Examination of six isolates and a vaccine strain. *Infect Immun* 38:731-738, 1982.
23. **Schnitzer TJ**: Identification of a new non-collagenous protein from avian bone. In: "Current Advances in Skeletogenesis", (Silbermann M, Slavkin HC, eds.), pp. 34-37, Elsevier Publishing Co., Amsterdam, 1982.
24. Strongwater SL, Annesley TM, **Schnitzer TJ**: Myocardial involvement in polymyositis. *J Rheum* 10:459-463, 1983.
25. Gouvea V, Huang DD, Ramos T, **Schnitzer TJ**: Myocardial involvement in polymyositis. *J Rheum* 10:459-463, 1983

COMPLETED PUBLICATIONS: (continued)

26. **Schnitzer TJ**, Rosenberger J, Huang DD, Gouvea V, Ramos T, Hassett K: Molecular biology and pathogenicity of avian reovirus. In: "Double-stranded RNA Viruses", (Compans, RW and Bishop, DHL, eds.), Elsevier Publishing Co., New York, 1983.
27. Dreyfus JN, **Schnitzer TJ**: Pathogenesis and differential diagnosis of the swan-neck deformity. *Sem Rheum* 13:200-211, 1983.
28. Ytterberg SR, Huard TK, **Schnitzer TJ**: Effects of serum from patients with systemic lupus erythematosus on leukocyte cytotoxicity: Modulation of NK activity and ADCC. *J Rheum* 10:906-912, 1983.
29. Ytterberg SR, **Schnitzer TJ**: Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: Roles of disease activity and serum interferon. *Ann Rheum Dis* 43:457-461, 1984.
30. Strongwater SL, Dorovini-Zis K, Ball RD, **Schnitzer TJ**: A murine model of polymyositis induced by coxsackievirus B1 (Tucson strain). *Arth Rheum* 27:433-442, 1984.
31. Huang DD, **Schnitzer TJ**: Detection of genomic differences between the avian reovirus isolate S1133 and its high passage derivative P100. *Avian Dis* 28:799-803, 1984.
32. **Schnitzer TJ**: Protein coding assignment of the S genes of the avian reovirus S1133. *Virology* 141:167-170, 1985.
33. Annesley TM, Strongwater SL, **Schnitzer TJ**: MM suboenzymes of creatinine kinase as an index of disease activity in polymyositis. *Clin Chem* 31:402-406, 1985.
34. Fudman EJ, **Schnitzer TJ**: Dermatomyositis without creatine kinase elevation: A poor prognostic sign. *Am J Med* 80(2):329-332, 1986.
35. Fudman EJ, **Schnitzer TJ**: Clinical and biochemical characteristics of autoantibody systems in polymyositis and dermatomyositis. *Sem Arth Rheum* 15(4):255-260, 1986.
36. Huang DD, Nugent MA, Rosenberger JK, **Schnitzer TJ**: Association of avian reovirus M and S genes with viral behavior in vivo. I. Viral persistence. *Avian Disease* 31:438-445, 1987
37. Huang DD, Nugent MA, Rosenberger JK, **Schnitzer TJ**: Association of avian reovirus M and S genes with viral behavior in vivo. II. Viral pathogenicity. *Avian Disease* 31:446-454, 1987.
38. Thonar EJ-MA, **Schnitzer TJ**, Kuettner KE: Quantification of keratan sulfate in blood as a marker of cartilage catabolism. *J Rheum* 14:23-24, 1987.

COMPLETED PUBLICATIONS: (continued)

39. Sweet MBE, Coelho A, Schnitler CM, **Schnitzer TJ**, Lenz ME, Jahim I, Kuettner KE, Thonar EJ-MA: Serum keratan sulphate levels in osteoarthritis patients. *Arth Rheum* 31:648-652, 1988.
40. Block JA, **Schnitzer TJ**, Andersson GBJ, Lenz ME, Jeffery R, McNeill TW, Thonar EJ-MA: The effect of chemonucleolysis on serum keratan sulfate levels in humans. *Arth Rheum* 32:100-104, 1989.
41. Barone-Varelas J, **Schnitzer TJ**, Meng Q, Otten L, Thonar EJ-MA: Age related difference in the metabolism of proteoglycans in bovine articular explants maintained in the presence of insulin-like growth factor I. *Conn Tis Res* 26:1-20, 1991.
42. Thonar EJ-MA, Manicourt DM, Williams JM, Lenz ME, Sweet MBE, **Schnitzer TJ**, Otten L, Glant T, and Kuettner KE: Circulating keratan sulfate: A marker of cartilage proteoglycan catabolism in osteoarthritis. *J Rheum (suppl. 27)* 18:24-26, 1991.
43. Deal CL, **Schnitzer TJ**, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F: Treatment of arthritis with topical capsaicin: A double-blind trial. *Clin Therap* 13:383-395, 1991.
44. Champion GV, McCrae F, **Schnitzer TJ**, Lenz ME, Dieppe PA, Thonar EJ-MA: Levels of keratan sulfate in the serum and synovial fluid of patients with osteoarthritis of the knee. *Arthr Rheum* 34:1254-1259, 1991.
45. Thonar EJ-MA, Manicourt DM, Williams JM, Fuhuda K, Sweet MBE, Champion GV, Lenz ME, **Schnitzer TJ**, Kuettner KE: Serum keratan sulfate: A measure of the cartilage proteoglycan metabolism. In "Articular Cartilage and Osteoarthritis", (Kuettner K.E., Schylerbach R., Peyron J.G., and Hascall V.C., eds.). Raven Press, New York, 1992, pp. 429-445.
46. **Schnitzer TJ**: Treatment of osteoarthritis - an updated strategy. *Postgrad Med* 93:89-91, 1993.
47. **Schnitzer TJ**, Popovich JM, Andersson GBJ, Andriacchi TP: Effect of piroxicam on gait in patients with osteoarthritis of the knee. *Arthr Rheum* 36:1207-1213, 1993.
48. **Schnitzer TJ**: Neuropeptides, capsaicin and musculoskeletal pain. *Sem Arthr* 23(S3):1-2, 1994.
49. **Schnitzer TJ**: Topical capsaicin therapy for osteoarthritis pain: Achieving a maintenance regimen. *Sem Arthr* 23(S3):34-40, 1994.
50. Broderick LS, Turner DA, Renfrew DL, **Schnitzer TJ**, Huff JP, Harris CH: Osteoarthritis: Evaluation of articular cartilage with fast spin echo imaging. *Amer J Radiology* 162:99-103, 1994.

COMPLETED PUBLICATIONS: (continued)

51. **Schnitzer TJ**: NSAIDs in orthopaedic practice: Management guidelines for arthritis patients. *Contemporary Orthopaedics*, 301, 383-389, 1995.
52. **Schnitzer TJ**: Biomechanics of gait in patients with varus gonarthrosis. *Rheum in Eur* 24:87-89, 1995.
53. **Schnitzer TJ**, Ballard IM, Constantine G, McDonald P: Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. *Clinical Therapeutics* 17:602-612, 1995.
54. Amsterdam EA, Helfand M, **Schnitzer TJ**, Weir GC, Young CD: Following the patient with stable chronic disease. *Patient Care* 29:22-42, 1995.
55. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, **Schnitzer TJ**: Guidelines for the medical management of osteoarthritis. Part I. osteoarthritis of the hip. *Arthr Rheum* 38:1535-1540, 1995.
56. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, **Schnitzer TJ**: Guidelines for the medical management of osteoarthritis. Part II. osteoarthritis of the knee. *Arthr Rheum* 38:1541-46, 1995.
57. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, **Schnitzer TJ**, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ: Double-blind placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. *Arthr Rheum* 38:1581-88, 1995.
58. **Schnitzer TJ**: NSAIDs in orthopedic practice: Managed guidelines for arthritis patients. *Contemporary Orthopaedics* 30:383-389, 1995.
59. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St. Clair EW, **Schnitzer TJ**, Johnston JM: CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. *Br J Rheum* 35:231-240, 1996.
60. **Schnitzer TJ**, Penmetcha M: Viral arthritis. *Curr Opin Rheumatol* 8:341-345, 1996.
61. **Schnitzer TJ**: Goals of long-term management of arthritis with NSAIDs. *Amer J Man Care* 2:5-9, 1996.
62. Michalska M, **Schnitzer TJ**: Management of osteoarthritis in the managed care setting. *Amer J Man Care* 2:S27-S34, 1996.
63. **Schnitzer TJ**, Constantine G: Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. *J Rheum* 24:S23-31, 1997.

COMPLETED PUBLICATIONS: (continued)

64. **Schnitzer TJ**, Yocum DE, Michalska M, Balias R, Snider ME, Hays A, Thurmond LM, Johnston JM: Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. *J Rheum* 24:1031-1036, 1997.
65. Block JA, **Schnitzer, TJ**: Therapeutic approaches to osteoarthritis. *Hospital Practice* 32: 159-164, 1997.
66. **Schnitzer TJ**, Donahue, JR, Toomey EP, Holtby RM, Scuderi GR, Adams PL, Poland MP: Effect of nabumetone on hemostasis during arthroscopic knee surgery. *Clin Therapeutics* 20: 110-124, 1998.
67. Rauck, RL, Gargiulo, CA, Ruoff, GE, **Schnitzer, TJ**, Trapp, RG: Chronic low back pain: new perspectives and treatment guidelines for primary care: Part I. *Managed Care Interface* 1(2): 72-77, 1998
68. Rauck, RL, Gargiulo, CA, Ruoff, GE, **Schnitzer, TJ**, Trapp, RG: Chronic low back pain: new perspectives and treatment guidelines for primary care: Part II. *Managed Care Interface* 1(3): 71-75, 1998
69. **Schnitzer TJ**, DiPrimeo D, Vavra I: Safety profile of bromfenac sodium. *Amer Jour Ortho*: 22-28, 1998
70. Saag KG, Emkey R, **Schnitzer TJ**, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice M-P, Czechur M, Daifotis AG; Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *N Eng J Med* 339:292-299, 1998
71. Sharma L, Hurwitz DE, Thonar E J-M A, Sum JA, Lenz ME, Dunlop DD, **Schnitzer TJ**, Kirwan-Mellis G, Andriacchi TP: Knee adduction moment, serum hyaluronan level, and disease severity in medical tibiofemoral osteoarthritis. *Arthr Rheum* 41:1233, 1998.
72. Barrett B, Bjorkman DJ, Brandt KD, Cryer B, De Broe ME, Gault MH, Henrich WL, Katz WA, Kimmey M, Porter GA, Ruoff GE, **Schnitzer TJ**, Singh G, Tolman KG, Warnock DG, Whelton A: Non-narcotic analgesics: renal and GI considerations. *Clinician* 16(4), 1998
73. **Schnitzer TJ**: Non-NSAID pharmacologic treatment options for the management of chronic pain. *Am J Med* 105:45S-52S, 1998.
74. Mehlich DE, Markenson J, **Schnitzer TJ**: The efficacy of nonsteroidal anti-inflammatory drugs for acute pain. *Cancer Control* 6: S5-9, 1999.
75. **Schnitzer TJ**, Olsen WH, Kamin M: Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain. *Arth Rheum* 42: 1370, 1999.

COMPLETED PUBLICATIONS: (continued)

76. **Schnitzer TJ:** Managing chronic pain with tramadol in elderly patients. *Clin Geriatrics* 7: 35-45, 1999.
77. **Schnitzer TJ:** Pathophysiology of Glucocorticoid-Induced Osteoporosis. *J. Clin Rheum* 5:S10-15, 1999.
78. **Schnitzer TJ,** Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW: Double-blind, placebo-controlled trial to evaluate the safety, tolerability, and effective dose range of rofecoxib in patients with rheumatoid arthritis. *Clin Therapeutics* 21: 1688-1702, 1999.
79. Ehrich EW, **Schnitzer TJ,** McIlwain H, Levy R, Wolfe F, Weisman M, Zeng Q, Morrison B, Bolognese J, Seidenberg B, Gertz BJ: Effect of specific cox-2 inhibition in osteoarthritis of the knee: a 6-week double-blind, placebo-controlled pilot study of rofecoxib. *J. Rheum* 26:2438-2447, 1999.
80. Yocum DE, Allard S, Cohen SB, Emery P, Flipo RM, Goobar J, Jayawardena S, Job-Deslandre C, Jubb RW, Kruger K, Vaz AL, Manger B, Mur E, Nygaard H, Peter HH, Rainer F, Sack MR, Schiff MH, **Schnitzer TJ,** Trigg LB, Whatmough I, Schmidt AG: Microemulsion formulation of cyclosporin (sandimmun neoral®) versus sandimmun®: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. *Rheumatology* 39: 156-164, 2000.
81. **Schnitzer TJ,** Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pincher A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur DE, Thompson DE, Yates J, Orloff JJ: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. *Ageing Clin Exp Res* 12: 1-12, 2000.
82. **Schnitzer TJ,** Gray WL, Paster RZ, Kamin M: Efficacy of tramadol in treatment of chronic low back pain. *J. Rheum.* 27:772-778, 2000.
83. Goker B, Doughan AM, **Schnitzer TJ,** Block JA: Quantification of progressive joint space narrowing in osteoarthritis of the hip: longitudinal analysis of the contralateral hip after total hip arthroplasty. *Arth Rheum* 43: 988-994, 2000.
84. Altman RD, Hochberg MC, Moskowitz RW, **Schnitzer TJ:** Recommendations for the medical management of osteoarthritis of the hip and knee. *Arth Rheum* 43: 1905-1915, 2000.
85. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferrz M, Hawkey CJ, Hochberg MC, Kvein TK, **Schnitzer TJ,** Weaver A. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. *N Eng J Med* 343: 1520-1528. 2000.

COMPLETED PUBLICATIONS: (continued)

86. **Schnitzer TJ**: Tramadol: Role in management of pain in elderly patients. Home Healthcare Consultant 7:27-34, 2000.
87. Hurwitz DE, Ryals AR, Block JA, Sharma L, **Schnitzer TJ**, Andriacchi TP: Knee pain and joint loading in subjects with knee osteoarthritis. J Orth Res 18:572-579, 2000.
88. Russell IJ, Kamin M, Sager DS, Bennett RM, **Schnitzer TJ**, Green JA, Katz WA: Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheum 6: 250-257, 2000.
89. **Schnitzer TJ**: Osteoarthritis Management: The Role of Cyclooxygenase-2-Selective Inhibitors. Clin Therapeutics 23: 313-326, 2001.
90. **Schnitzer TJ**: Cyclooxygenase-2-Specific Inhibitors: Are They Safe? Am J Med 110: 46S-49S, 2001.
91. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Pubelle PEE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, **Schnitzer TJ**, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MOR, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, and Daifotis A: Two-Year Effects of Alendronate on Bone Mineral Density and Vertebral Fracture in Patients Receiving Glucocorticoids. Arthr Rheum 44: 202-211, 2001.
92. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, Shea B, Tugwell P, Wells G, **Osteoporosis Research Group (ORAG)**. A meta-analysis of etidronate for the treatment of post-menopausal osteoporosis. Osteoporosis International 12: 140-151, 2001.
93. Murphy GS, Weiss S, McClung M, **Schnitzer T**, Cerchio K, Connor J, Krupa D, Gertz GJ, MK-677/Alendronate Study Group. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal women. J. Clin. Endrocr Metabol 86: 1116-1125, 2001.
94. **Schnitzer TJ**: Update on alendronate for osteoporosis: once-weekly therapy. Expert Opin. Pharmacother. 2: 1461-1472, 2001.
95. Moreland L, Gugliotti R, King K, Chase W, Weiseman M, Greco T, Fife R, Korn J, Simms, R, Tesser J, Hillson J, Caldwell J, **Schnitzer T**, Lyons D, Schwertschlag U: Results of a phase I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Research 3: 247-252, 2001.

COMPLETED PUBLICATIONS: (continued)

96. Pincus T, Koch GG, Sokka T, Lefkowitz J, Wolfe F, Jordan JM, Luta G, Callahan LF, Wang X, Schwartz T, Abramson SB, Caldwell JR, Harrell RA, Kremer JM, Lautzenheiser RL, Markenson JA, **Schnitzer TJ**, Weaver A, Cummins P, Wilson A, Morant S, Fort J. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. *Arth Rheum* 44: 587-598, 2001.
97. **Schnitzer TJ**: Is concern about cardiovascular events with the new coxib class of drugs justified? *Medscape Women's Health* 6:8, 2001.
98. Bolognese J, Ehrich E, **Schnitzer TJ**: Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints. *J. Rheum* 40: 2700-2704, 2001.
99. Bell GM, **Schnitzer TJ**: COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly. *Clinics in Geriatric Medicine* 17: 489-502, 2001.
100. **Schnitzer TJ**, Kong SX, Mavros P, Straus WL, Watson DJ: Use of nonsteroidal antiinflammatory drugs and gastroprotective agents before the COX-2 era: Analysis of a large US claims database. *Clinical Therapeutics* 23: 1984-1998, 2001.
101. Geba FP, Weaver AL, Polis AB, Dixon ME, **Schnitzer TJ**: Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. *JAMA* 287: 64-71, 2002.
102. **Schnitzer TJ**: Update of ACR guidelines for osteoarthritis: role of the coxibs. *Journal of Pain & Symptom Management* 23:S24-30, 2002.
103. Greenspan SL, Schneider DL, McClung MR, Miller PD, **Schnitzer TJ**, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME: Alendronate improves bone density in elderly female long-term care facility residents: a randomized, double-blind, placebo-controlled trial. *Ann Int Med* 136:742-746, 2002.
104. **Schnitzer TJ**, Hochberg MC: COX-2 selective inhibitors in the treatment of arthritis. *Cleveland Clinic Journal of Medicine* 69:S120-130, 2002.
105. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, **Schnitzer T**, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stampler DA: Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. *Arthritis Rheum.* 46:2020-2028, 2002.

COMPLETED PUBLICATIONS: (continued)

106. Greenspan SL, Bone G 3rd, **Schnitzer TJ**, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd, Kaur A, Peverly CA, Orloff JJ, Rizzoli R: Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. *J Bone Miner Res* 17:1988-96, 2002.
107. Osteoporosis Methodology Group and **the Osteoporosis Research Advisory Group**: Meta-analyses of therapies for postmenopausal osteoporosis. *Endocrine Reviews* 23:495-578, 2002.
108. Gottesdiener K, **Schnitzer T**, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ: Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. *Rheumatology* 41:1052-61, 2002.
109. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, **Schnitzer TJ**, Yu Q, Bombardier C: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. *Gastroenterology* 124: 228-292, 2003.
110. **Schnitzer TJ**: The new analgesic combination tramadol/acetaminophen. *Europ J Anesthesiol* 20:S13-18, 2003.
111. Bolognese JA, **Schnitzer TJ**, Ehrich EW: Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. *Osteoarthritis Cartilage* 11:499-507, 2003.
112. Siris ES, Bilezikian JP, Rubin MR, Black DM, Bockman RS, Bone HG, Hochberg MC, McClung MR, **Schnitzer TJ**: Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. *J Clin Endocrinol Metab.* 88:3482-6, 2003.
113. **Schnitzer TJ**, Kong SX, Mitchell JH, Mavros P, Watson DJ, Pellissier JM, Straus WL: An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. *Clin Ther.* 25: 3162-3172, 2003.
114. **Schnitzer TJ**: Means, responders, and meaning: evaluation of clinical trials in osteoarthritis. *Arthritis Rheum* 48:3001-3003, 2003.
115. Goemaere S, Liberman UA, Adachi JD, Hawkins F, Lane N, Saag KG, **Schnitzer T**, Kaufman JM, Malice MP, Carofano W, Daifotis A: Incidence of Nonvertebral Fractures in Relation to Time on Treatment and Bone Density in Glucocorticoid-Treated Patients: A Retrospective Approach. *J Clin Rheumatol.* 9:170-175, 2003.
116. **Schnitzer TJ**, Wehren LE: The patient with a fragility fracture: an evolving role for the orthopedic surgeon. *Quart. J. Med.* 97:101-104, 2004.

COMPLETED PUBLICATIONS: (continued)

117. **Schnitzer TJ**, Ferraro A, Hunsche E, Kong SX: A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. *J. Pain Sym Man* 29: 72-95, 2004.
118. Miller PD, **Schnitzer T**, Emkey R, Orwoll E, Rosen C, Ettinger M, Vandormael K, Daifotis A. Weekly oral alendronic acid in male osteoporosis. *Clinical Drug Investigation* 24: 333-341, 2004.
119. **Schnitzer TJ**, Burmester GR, Muysler E, Hochberg MC, Doherty M, Ehram E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona, A Hawkey C. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. *Lancet* 364: 665-674, 2004.
120. Farkouh ME, Kirschner H, Harrington RA, Ruland S, Verheugt FWA, **Schnitzer TJ**, Burmester GR, Muysler E, Hochberg MC, Doherty M, Ehram E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey C, Chesebro JH. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. *Lancet* 364: 675-684, 2004.
120. Altman RD, Akermark C, Beaulieu AD, **Schnitzer T**. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. *Osteoarthritis Cartilage* 12: 642-649, 2004.
121. **Schnitzer TJ**, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poor G. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 51: 549-57, 2004.
122. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, **Schnitzer TJ**. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. *Arthritis Rheum.* 51: 746-754, 2004.
123. Mazzuca SA, Brandt KD, Katz BP, Lane KA, Bradley JD, Heck LW, Hugenberg ST, Manzi S, Moreland LW, Oddis CV, **Schnitzer TJ**, Sharma L, Wolfe F, Yocum DE. Subject retention and adherence in a randomized placebo-controlled trial of a disease-modifying osteoarthritis drug. *Arthritis Rheum.* 51: 933-940, 2004.

COMPLETED PUBLICATIONS: (continued)

124. **Schnitzer TJ**, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. *Curr Med Res Opin.* 21:151-61, 2005.
125. **Schnitzer TJ**, Weaver AL, Polis AB, Petruschke RA, Geba GP. Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Patients with Osteoarthritis of the Knee. A Combined Analysis of the VACT Studies. *J Rheumatol.* 32:1093-105, 2005.
126. Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, **Schnitzer TJ**, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. Effects of doxycycline on progression of osteoarthritis: Results of a randomized, placebo-controlled, double-blind trial. *Arthritis Rheum.* 52:2015-25., 2005.
127. Lee C, Hunsche E, Balshaw R, Kong SX, **Schnitzer TJ**. Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis *Arthritis Rheum.* 53::510-8, 2005.
128. **Schnitzer TJ**, Kivitz AJ, Lipetz RS, Sanders N, Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. *Arthritis Rheum.* 53:827-37, 2005.
129. Bombardier C, Laine L, Burgos-Vargas R, Davis B, Day R, Bosi Ferrz M, Hawkey CJ, Hochberg MC, Kvein TK, **Schnitzer TJ**, Weaver A. Response to expression of concern regarding VIGOR study. *N Engl J Med.* 354:1196-9, 2006.
130. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, Bradley JD, Bingham CO 3rd, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR Jr, Oddis CV, Wolfe F, Molitor JA, Yocum DE, **Schnitzer TJ**, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med.* 354:795-808, 2006.
131. **Schnitzer TJ**. Pain management today-optimising the benefit/risk ratio: defining the role of weak opioids and combination analgesics. *Clin Rheumatol.* 25: Suppl 7: 1, 2006.
132. **Schnitzer TJ**. Update on guidelines for the treatment of chronic musculoskeletal pain. *Clin Rheumatol.* 25 Suppl 7:22-9, 2006.

COMPLETED PUBLICATIONS: (continued)

133. Smugar SS, **Schnitzer TJ**, Weaver AL, Rubin BR, Polis AB, Tershakovec AM: Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. *Curr Med Res Opin.* 22:1353-67, 2006.
134. Greenberg JA, Roth EJ, Wuermsler LA, Almagor O, **Schnitzer TJ**: Osteoporosis Treatment for Patients with Stroke. *Top Stroke Rehabil.* 14:62-67, 2007.
135. Hellio Le Graverand MP, Vignon EP, Brandt KD, Mazzuca SA, Piperno M, Buck R, Charles HC, Hunter DJ, Jackson CG, Kraus VB, Link TM, **Schnitzer TJ**, Vaz A, Wyman B: Head-to-head comparison of the Lyon schuss and fixed flexion radiographic techniques. Long-term reproducibility in normal knees and sensitivity to change in osteoarthritic knees. *Ann Rheum Dis* 67: 1562 – 1566, 2008.
136. Eckstein F, Buck RJ, Burstein D, Charles HC, Crim J, Hudelmaier M, Hunter D, Hutchins G, Jackson C, Byers Kraus V, Lane NE, Link TM, Majumdar S, Mazzuca S, Prasad PV, **Schnitzer TJ**, Taljanovic MS, Vaz A, Wyman B, Hellio Le Graverand MP: Precision of 3.0 Tesla Quantitative Magnetic Resonance Imaging of cartilage morphology in a multi center clinical trial. *Ann Rheum Dis* 67: 1683 – 1688, 2008.
137. Mazzuca SA, Hellio Le Graverand MP, Vignon E, Hunter DJ, Jackson CG, Kraus VB, Link TM, **Schnitzer TJ**, Vaz A, Charles HC. Performance of a non-fluoroscopically assisted substitute for the Lyon schuss knee radiograph: quality and reproducibility of positioning and sensitivity to joint space narrowing in osteoarthritic knees. *Osteoarthritis Cartilage* 16:1555-9, 2008.
138. Greenberg JA, **Schnitzer TJ**, Gaebler-Spira D. Bone Health in Children with Cerebral Palsy. *Current Pediatric Reviews* 4: 187-193, 2008.
139. **Schnitzer TJ**. From basic biology to therapeutic potential. *Osteoarthritis Cartilage.* 16: S1, 2008.
140. Baliki MN, Geha PY, Jabakhanji R, Harden N, **Schnitzer TJ**, Apkarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. *Molecular Pain* 4:47, 2008.
141. **Schnitzer TJ**, Tesser JR, Cooper KM, Altman RD. A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. *Osteoarthritis Cartilage* 17:1-7, 2009.
142. Hellio Le Graverand MP, Buck RJ, Wyman BT, Vignon E, Mazzuca SA, Brandt KD, Piperno M, Charles HC, Hudelmaier M, Hunter DJ, Jackson C, Kraus VB, Link TM, Majumdar S, Prasad PV, **Schnitzer TJ**, Vaz A, Wirth W, Eckstein F. Subregional femorotibial cartilage morphology in women - comparison between healthy controls and participants with different grades of

- radiographic knee osteoarthritis. *Osteoarthritis Cartilage*. 17: 1177-1185, 2009.
143. Karlsson J, Pivodic A, Aguirre D, **Schnitzer TJ**. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. *J Rheumatol*. 36:1290-7, 2009.
144. Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, **Schnitzer TJ**. Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial. *J Rheumatol*. 36:1705-14, 2009.
145. White WB, **Schnitzer TJ**, Fleming R, Duquesroix B, Beekman M. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. *Am J Cardiol*. 104:840-845, 2009.
146. Roth T, Price JM, Amato DA, Rubens RP, Roach JM, **Schnitzer TJ**. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. *Primary Care Companion to the Journal of Clinical Psychiatry* 11:292-301, 2009.
147. Hellio Le Graverand MP, Buck RJ, Wyman BT, Vignon E, Mazzuca SA, Brandt KD, Piperno M, Charles HC, Hudelmaier M, Hunter DJ, Jackson C, Kraus VB, Link TM, Majumdar S, Prasad PV, **Schnitzer TJ**, Vaz A, Wirth W, Eckstein F. Change in regional cartilage morphology and joint space width in osteoarthritis participants versus healthy controls - a multicenter study using 3.0 Tesla MRI and Lyon Schuss radiography. *Ann Rheum Dis*. 69:155-162, 2010.
148. Buck RJ, Wyman BT, Le Graverand MP, Wirth W, Eckstein F; A9001140 Investigators. An efficient subset of morphological measures for articular cartilage in the healthy and diseased human knee. *Magn Reson Med*. 63:680-90, 2010.
149. **Schnitzer TJ**, Kivitz A, Frayssinet H, Duquesroix B. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. *Osteoarthritis Cartilage*. 18:629-639, 2010.

BOOK CHAPTERS:

1. Chanock RM, Richman DD, Murphy BR, Spring SB, **Schnitzer TJ**, Richardson LS: Current approaches of viral immunoprophylaxis. In: "Viral Immunology and Immunopathology", (Al Notkins, ed.), Academic Press, 1975, pp. 291-316.
2. Denman AM, Appleford DJ, Imrie RC, Kinsley MJ, Pelton BK, **Schnitzer TJ**: Lymphocytes and virus infections in the connective tissue diseases. In: "Proceedings, Conference on Rheumatic Disease", Cambridge, England, 1976.
3. Denman AM, Appleford DJ, Imrie RC, Kinsley MJ, Pelton BK, **Schnitzer TJ**: Viral replication in lymphocytes and the pathogenesis of connective tissue diseases. In: "Bayer Symposium VI: Experimental Models of Chronic Inflammatory Disease", Springer-Verlag, 1977, pp. 77-92.
4. **Schnitzer TJ**: Viral arthritis. In: "Textbook of Rheumatology", (Kelley WN, Harris E, Ruddy S, Sledge CB, eds.), W.B. Saunders Company, Philadelphia, 1985, pp. 1450, 1556.
5. Ytterberg SR, **Schnitzer TJ**: Coxsackievirus B1-induced murine polymyositis. In: "Handbook of Animal Models for the Rheumatic Diseases, Vol. 1", (Greenwald Ra, Diamond HS, eds.) CRC Press, Boca Raton, Florida, 1988, pp. 147-156.
6. **Schnitzer TJ**, Karakusis PH: Infectious arthritis. In: "Primer on the Rheumatic Diseases", (Schumacher RH, ed., Klippel JH, Robinson DR, assoc. eds.), Arthritis Foundation, Atlanta, Georgia, 1988, pp. 181-188.
7. Ytterberg SR, **Schnitzer TJ**: Coxsackievirus B1-induced murine polymyositis. In: "Handbook of Animal Models for the Rheumatic Diseases, Vol. 1", (Greenwald Ra, Diamond HS, eds.), CRC Press, Boca Raton, Florida, 1988, pp. 147-156.
8. **Schnitzer TJ**: Viral arthritis. In: "Textbook of Rheumatology", (Kelley WN, Harris E, Ruddy S, Sledge CB, eds.), W.B. Saunders Company, Philadelphia, 1989, pp. 1611-1624.
9. Thonar EJ-MA, Williams JM, Sweet MBE, Maldonado BA, Lenz ME, **Schnitzer TJ**, and Kuettner KE: Keratan sulfate as a marker for cartilage proteoglycan catabolism. In: "Clinical Impact of Bone and Connective Tissue Markers", (Lindh E, Thorell JI, eds.), Academic Press, London, 1989, pp. 229-233.

BOOK CHAPTERS: (continued)

10. Thonar EJ-MA, Williams JM, Sweet MBE, Maldonado BA, Lenz ME, **Schnitzer TJ**, and Kuettner KE: Studies of the metabolism of keratan sulfate-bearing proteoglycans of cartilage. In: "Keratan Sulphate Chemistry, Biology, Chemical Pathology", (Greiling H, Scott JE, eds.), The Biochemical Society, London, pp. 184-190, 1989.
11. Thonar EJ-MA, Williams JM, Lenz ME, Sweet MBE, Otten L, Campion G, **Schnitzer TJ**, Kuettner KE: Measurement of serum keratan sulfate provides important information about the metabolism of cartilage proteoglycans in vivo. In: "Methods in Cartilage Research", (Maroudas, A. and Kuettner, K.E., eds.), Academic Press, New York, pp. 345-347, 1990.
12. Thonar EJ-MA, Williams JM, Maldonado BA, Lenz ME, **Schnitzer TJ**, Campion GV, Kuettner KE: Serum keratan sulfate concentration as a measure of the catabolism of cartilage proteoglycans. In: "Monoclonal Antibodies, Cytokines, and Arthritis: Mediators of Inflammation and Therapy", (Kresina, T., ed.), Marcel Dekker, New York, pp. 373-398, 1991.
13. Carstens JH, Kowal A, **Schnitzer TJ**: Cyclosporine in rheumatoid arthritis. In: "Immunomodulators in the Rheumatic Diseases", (Furst D, Weinblatt, eds.), Marcel Dekker, Inc., New York, New York, 1990.
14. **Schnitzer TJ**: Management of Osteoarthritis. In: "Arthritis and Allied Conditions", (McCarty DJ, Koopman WJ, eds.). Lea & Febiger, Philadelphia, pp. 1761-1769, 1992.
15. **Schnitzer TJ**: Polymyositis/Dermatomyositis. In: "Quick Reference to Internal Medicine: Outline Format", (Bone R, Rosen RL, eds.). Igaku-Shoin, New York, pp. 1197-1198, 1994.
16. **Schnitzer TJ**: Osteoarthritis. (Degenerative Joint Disease). In: "Cecil Textbook of Medicine" (Bennett JC, Plum F, eds.) 20th ed. WB Saunders Co, Philadelphia, PA, pp. 1517-1521, 1996.
17. Block JA, **Schnitzer TJ**: Osteoarthritis. In: "Conn's Current Therapy 1999" (Rakel RE, ed.) WB Saunders Co, Philadelphia, PA, pp. 1007-1010, 1999
18. **Schnitzer TJ**: Osteoarthritis. (Degenerative Joint Disease). In: "Cecil Textbook of Medicine" (Bennett JC, Goldman, eds.) 21st ed. WB Saunders Co, Philadelphia, PA, 2000.

EDITORSHIPS:

1. Schnitzer TJ: Section Editor: Osteoporosis and Metabolic Bone Disease. Current Rheumatology Reports 5: 43-81, 2003.
2. Schnitzer TJ: Editor-in-Chief: Current Osteoporosis Reports. 2003-present